...Cantabio detailed how it identified and characterized its DJ-1 pharmacological chaperones. Through a partnership with NovAliX S.A.S....
...filed Company Cantabio Pharmaceuticals Inc. Companies and Institutions Mentioned Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), Sunnyvale, Calif. NovAliX S.A.S....

...by Kyowa Hakko to a January deal to discover small molecules that modulate protein-protein interactions. NovAliX...
...as research funding and milestones. The partners declined to disclose details (see BioCentury, Jan. 21). NovAliX S.A.S....

...through the IND stage. The companies declined to disclose details. Inventiva S.A.S. , Daix, France NovAliX S.A.S....

...clinical milestones and royalties on antibodies licensed by Kyowa Discovery/Preclin Jan-13 NovAliX S.A.S. Research collaboration Use NovAliX's...

...NovAliX partnered with Kyowa to use NovAliX's Graffinity fragment-based screening technology to discover and develop small...
...Kyowa. The technology combines microarrays with surface plasmon resonance (SPR) imaging to detect compound-protein interactions. NovAliX...
...fee, as well as research funding and milestones. The companies declined to disclose further details. NovAliX S.A.S....

...NovAliX S.A.S. (Illkirch, France) partnered with Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to use NovAliX's Graffinity...
...NovAliX will receive an undisclosed technology access fee, as well as research funding and milestones. NovAliX...

...Servier announced a deal with NovAliX to use NovAliX's Graffinity fragment-based screening technology to discover small...
...and research funding. NovAliX declined to disclose details. Servier could not be reached for details. NovAliX S.A.S....

...Servier (Neuilly-sur-Seine, France) announced a deal with NovAliX S.A.S. (Illkirch, France) to use NovaAliX's Graffinity fragment-based screening...
...Servier. The technology combines microarrays with surface plasmon resonance (SPR) imaging to detect compound-protein interactions. NovAliX...

...Teijin. NovAliX will receive technology access fees and other research funding. Details were not disclosed. NovAliX S.A.S....